535 related articles for article (PubMed ID: 32125404)
1. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
Wouters OJ; McKee M; Luyten J
JAMA; 2020 Mar; 323(9):844-853. PubMed ID: 32125404
[TBL] [Abstract][Full Text] [Related]
2. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V; Mailankody S
JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
[TBL] [Abstract][Full Text] [Related]
3. Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.
Moore TJ; Zhang H; Anderson G; Alexander GC
JAMA Intern Med; 2018 Nov; 178(11):1451-1457. PubMed ID: 30264133
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies.
Tay-Teo K; Ilbawi A; Hill SR
JAMA Netw Open; 2019 Jan; 2(1):e186875. PubMed ID: 30644967
[TBL] [Abstract][Full Text] [Related]
6. Estimated Cost of Developing a Therapeutic Complex Medical Device in the US.
Sertkaya A; DeVries R; Jessup A; Beleche T
JAMA Netw Open; 2022 Sep; 5(9):e2231609. PubMed ID: 36103178
[TBL] [Abstract][Full Text] [Related]
7. Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry.
Zhou EW; Jackson MJ; Ledley FD
JAMA Health Forum; 2023 Jul; 4(7):e231921. PubMed ID: 37450296
[TBL] [Abstract][Full Text] [Related]
8. Medical Marketing in the United States, 1997-2016.
Schwartz LM; Woloshin S
JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
[TBL] [Abstract][Full Text] [Related]
9. Labeling Changes and Costs for Clinical Trials Performed Under the US Food and Drug Administration Pediatric Exclusivity Extension, 2007 to 2012.
Sinha MS; Najafzadeh M; Rajasingh EK; Love J; Kesselheim AS
JAMA Intern Med; 2018 Nov; 178(11):1458-1466. PubMed ID: 30264138
[TBL] [Abstract][Full Text] [Related]
10. Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach.
Henderson RH; French D; Stewart E; Smart D; Idica A; Redmond S; Eckstein M; Clark J; Sullivan R; Keeling P; Lawler M
J Pharm Policy Pract; 2023 Jul; 16(1):84. PubMed ID: 37408046
[TBL] [Abstract][Full Text] [Related]
11. Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional study.
Moore TJ; Heyward J; Anderson G; Alexander GC
BMJ Open; 2020 Jun; 10(6):e038863. PubMed ID: 32532786
[TBL] [Abstract][Full Text] [Related]
12. Innovation in the pharmaceutical industry: New estimates of R&D costs.
DiMasi JA; Grabowski HG; Hansen RW
J Health Econ; 2016 May; 47():20-33. PubMed ID: 26928437
[TBL] [Abstract][Full Text] [Related]
13. Estimating the clinical cost of drug development for orphan versus non-orphan drugs.
Jayasundara K; Hollis A; Krahn M; Mamdani M; Hoch JS; Grootendorst P
Orphanet J Rare Dis; 2019 Jan; 14(1):12. PubMed ID: 30630499
[TBL] [Abstract][Full Text] [Related]
14. The price of innovation: new estimates of drug development costs.
DiMasi JA; Hansen RW; Grabowski HG
J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
[TBL] [Abstract][Full Text] [Related]
15. Economic return of clinical trials performed under the pediatric exclusivity program.
Li JS; Eisenstein EL; Grabowski HG; Reid ED; Mangum B; Schulman KA; Goldsmith JV; Murphy MD; Califf RM; Benjamin DK
JAMA; 2007 Feb; 297(5):480-8. PubMed ID: 17284698
[TBL] [Abstract][Full Text] [Related]
16. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
[TBL] [Abstract][Full Text] [Related]
17. Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.
Sachs RE; Gavulic KA; Donohue JM; Dusetzina SB
JAMA Health Forum; 2021 Oct; 2(10):e213177. PubMed ID: 35977163
[TBL] [Abstract][Full Text] [Related]
18. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.
Hsiue EH; Moore TJ; Alexander GC
Clin Trials; 2020 Apr; 17(2):119-125. PubMed ID: 32114790
[TBL] [Abstract][Full Text] [Related]
19. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
20. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
